High-risk clinic for melanoma surveillance is scalable

High-risk clinic for melanoma surveillance is scalable

(HealthDay)—A structured surveillance program for high-risk melanoma patients can be scaled and successfully replicated even in a primary care skin cancer clinic, according to a study published online March 17 in JAMA Dermatology.

Pascale Guitera, M.D., Ph.D., from the Melanoma Institute Australia at the University of Sydney, and colleagues examined the longer-term sustainability and expansion of a melanoma surveillance program for (full-body examinations every six months aided by total-body photography [TBP] and sequential digital dermoscopy imaging) to numerous practices, including a primary care clinic setting. The analysis included 593 patients assessed from 2012 to 2018 at three dermatology clinics and one primary care skin cancer clinic.

The researchers found 1,513 lesions were excised during follow-up, including 171 primary melanomas, and excision ratios were similar across the four centers. In the first two years, the risk for developing a new was 9 percent annually, which increased with time, particularly for those with multiple primary melanomas. The seven thicker melanomas (>1 mm Breslow thickness; 4.1 percent of melanomas) were mostly desmoplastic or nodular (four of seven), self-detected (two of seven), or clinician detected without the aid of TBP (three of seven). New melanomas (171) were most likely to be detected by a clinician with the aid of TBP (31.6 percent) followed by digital dermoscopy monitoring (29.2 percent).

"The findings of this cohort study suggest that the structured surveillance program may be implemented on a larger scale, including at primary care skin cancer clinics, with consistent and sustainable benefits observed," the authors write.

One author disclosed to a medical technology company and one disclosed ties to the pharmaceutical industry.

Explore further

Overall survival worse with multiple primary melanomas

More information: Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Journal information: JAMA Dermatology

Copyright © 2020 HealthDay. All rights reserved.

Citation: High-risk clinic for melanoma surveillance is scalable (2021, March 23) retrieved 25 May 2022 from https://medicalxpress.com/news/2021-03-high-risk-clinic-melanoma-surveillance-scalable.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors